DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
A phase 2 trial of BI 764532, dose 1 in small-cell lung cancer and neuroendocrine tumours, run by Boehringer Ingelheim, now recruiting.
Overview
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers is a phase 2 interventional study registered as NCT05882058 by Boehringer Ingelheim, with 204 participants planned, started 2023-10-13 and due to reach its primary completion in 2027-12-17. Interventions recorded: BI 764532, dose 1, BI 764532, dose 2 and Ventana DLL3 RxDx assay.
Similar pages
not linked directly; found by shared links- TrialDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Shares Boehringer Ingelheim, Neuroendocrine tumours and the tag pipeline.
- TrialA Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
Shares Boehringer Ingelheim and the tag pipeline.
- TrialA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
- TrialBeamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Shares Boehringer Ingelheim and the tag pipeline.
- TrialStudy of Oral MRT-2359 in Selected Cancer Patients
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
- TrialStudy of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Shares Small-cell lung cancer and the tag pipeline.
- TrialSNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Shares Small-cell lung cancer and the tag pipeline.